Last reviewed · How we verify
A Phase III, Prospective, Multicenter, Randomized, Open, Parallel Group Comparison of Lanreotide Autogel® (90 and 120 mg) Administered by Deep Subcutaneous Injection Every Four Weeks, With Sandostatin LAR Depot (20 and 30 mg) Administered by Intramuscular Injection, Every Four Weeks for Six Months, in the Treatment of Clinical Symptoms Associated With Carcinoid Syndrome
The aim of this study is to compare the efficacy and safety of lanreotide Autogel and Sandostatin LAR Depot, to see whether these two 28-day prolonged release formulations produce a similar clinical response in patients with carcinoid syndrome.
Details
| Lead sponsor | Ipsen |
|---|---|
| Phase | Phase 3 |
| Status | TERMINATED |
| Enrolment | 4 |
| Start date | 2004-07 |
| Completion | 2004-10 |
Conditions
- Malignant Carcinoid Syndrome
Interventions
- lanreotide Autogel (somatostatin analogue)
- Sandostatin long acting release (LAR) Depot (somatostatin analogue)
Primary outcomes
- Target symptom frequency (flushing or stool frequency).
Countries
United States